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Human bocavirus 1 (HBoV1) can persist in nasopharynx and tonsils. Using HBoV1 serology, 63	  
reverse-transcription polymerase chain reaction (PCR) for detecting messenger RNA (mRNA) and 64	  
quantitative PCR for HBoV1 genome load count, we studied in what extent the HBoV1 DNA loads 65	  
in nasopharynx correlates with acute infection markers. Tonsillar tissue, nasopharyngeal aspirate 66	  
and serum were obtained from 188 elective adeno-/tonsillectomy patients. Relatively high loads of 67	  
HBoV1 DNA were detected in the nasopharynx of 14 (7%) primarily asymptomatic subjects with 68	  
negative mRNA and/or serodiagnostic results. Quantitative HBoV1 DNA PCR may have lower 69	  
specificity than HBoV1 mRNA detection for diagnosing symptomatic infection. 70	  
 71	  




















Human bocavirus (HBoV) was discovered in 2005 and belongs to the Parvoviridae family [1]. It is 88	  
a non-enveloped single-stranded DNA virus causing mild to life-threatening respiratory tract 89	  
infections in young children. HBoV1 is primarily transmitted by the respiratory route [1]. Three 90	  
other human bocaviruses (HBoV2-4) have been discovered in stool and are considered enteric. 91	  
HBoV1 is a frequent finding in young children suffering from lower respiratory tract illnesses such 92	  
as bronchiolitis, wheezing, asthma and pneumonia [1,2]. The persistence of HBoV DNA in the 93	  
airways and tonsils has been under investigation lately. In a recent study, HBoV DNA was found in 94	  
tonsil squamous cell carcinoma tumors, prompting speculations of a possible causal association 95	  
[3,4]. The virus is known to persist for weeks or months in the respiratory tract whereby a 96	  
qualitative polymerase chain reaction (PCR) is insufficient as a diagnostic tool [1,2,5,6]. 97	  
Microbiological diagnosis is often incorrectly based on a qualitative multiplex PCR. The most 98	  
reliable diagnosis of acute HBoV1 infection is considered to be based on messenger RNA (mRNA) 99	  
or a high HBoV1 DNA load in nasopharyngeal aspirate (NPA), DNA in serum, and serology 100	  
[1,2,5,7]. HBoV1 DNA has been shown to also persist in adenoids and tonsils of children [8]. The 101	  
aim of this study was to evaluate if high HBoV1 DNA loads occur in NPA or tonsils in adeno-102	  
/tonsillectomy patients without acute HBoV1 infection, based on a documented lack of HBoV1 103	  
mRNA and/or IgM, the gold standards for diagnosis. We hypothesized that there is no active 104	  
bocavirus replication in persistent HBoV1 detection. 105	  
 106	  
METHODS 107	  
Study Population 108	  
Tonsil and nasopharyngeal samples were collected from 200 consecutive patients who underwent 109	  
adeno-/tonsillectomy at the Satakunta Central Hospital, Pori, Finland, between April 2008 and 110	  





clinical indication and written informed approval from the study subject or his/her parents. Out of 112	  
the 200 enrolled patients, 12 yielded low-quality samples. In total, 188 patients with a median age 113	  
of 12 years (range 1-65) underwent elective adeno-/tonsillectomy (n=143) or sole adenotomy 114	  
(n=45) and had sufficient and good quality biopsy samples for microbial and immunological studies 115	  
[9]. The main indications for tonsillectomy were recurrent tonsillitis in 43 (30%) and tonsillar 116	  
hypertrophy in 48 (34%) of 143 patients and for adenotonsillectomy, adenotonsillar hypertrophy in 117	  
40 of 143 (28 %) patients, respectively [9]. Other indications (8%) for adeno-/tonsillectomy were 118	  
e.g. throat abscess, recurrent fever, food remnants in tonsils and teeth braces. Indications for 119	  
adenotomy were hypertrophy in 17 (38%) and recurrent otitis in 28 (62%) of 45 patients. All the 120	  
study patients filled a standardized health questionnaire including respiratory symptoms 30 days 121	  
before and after the operation [9]. On the operation day 127 (67%) had no respiratory tract 122	  
symptoms, 37 (20%) reported mild respiratory symptoms and 24 (13%) had no data. 123	  
 124	  
Samples 125	  
Adeno-/tonsillectomy was performed by otorhinolaryngologists according to routine clinical 126	  
procedure. A part of the internal tonsillar tissue was instantly cut in 3-4 mm cubes, stored in 127	  
RNAlater, an RNA stabilization reagent (Qiagen, Hilden, Germany), incubated at +2-8 ºC until the 128	  
next working day and finally stored at -80 ºC [9]. Nasopharyngeal aspirate samples were collected 129	  
using a standardized procedure. If the aspirate yield was small, the collection was repeated after 130	  
administration of 2 ml physiologic saline. For viral analyses, a part of the tonsils and a 131	  
nasopharyngeal aspirate were stored in dry tubes at -80 °C [9]. The first sample of the paired serum 132	  
samples was collected during the tonsillectomy anesthesia and the follow-up sample was taken in a 133	  
median of 58 days (range 36-104).  134	  
  135	  





The study protocols were approved by the Ethics Committee of the Satakunta Central Hospital and 137	  
by the Ethics Committee of the Hospital District of Southwest Finland. 138	  
 139	  
Virus Diagnostics 140	  
Virus diagnostics of all NPA and tonsil samples was performed according to clinical routine using 141	  
PCR. Adenoid tissue samples were not analyzed. In-house real-time PCR assays were used to detect 142	  
HBoV1, rhinovirus, enterovirus, and respiratory syncytial virus as described previously [9]. Seeplex 143	  
RV12 ACE Detection (Seegene, Seoul, Korea) multiplex PCR assay was used for detection of 144	  
adenovirus, coronaviruses (229E/NL63 and OC43/HKU1), influenza A and B viruses, 145	  
metapneumovirus, parainfluenza virus types 1-3, respiratory syncytial virus group A and B, and 146	  
rhinovirus according to manufacturer’s instructions. Quantitative PCR (qPCR) was used for 147	  
measuring the HBoV1 DNA load [10]. Serological tests for HBoV1-specific IgM and IgG were 148	  
performed for 122 patients [5,11]. Serology of the adenotomy patients (n=45) was not analyzed. To 149	  
verify that the IgG results were HBoV1 specific, the serum samples were blocked with HBoV2 and 150	  
HBoV3 antigens. The mRNA expression levels of HBoV1 in NPA and tonsil samples were 151	  
analyzed by reverse-transcription PCR (RT-PCR) [7]. An RT-PCR detecting human beta-actin 152	  
mRNA was used as control for intactness of mRNA in the samples [12]. Virus PCR and qPCR were 153	  
done at the Department of Virology, University of Turku, Turku, Finland, and at the Department of 154	  
Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Serology was 155	  
analyzed at the Department of Virology, University of Helsinki and the RT-PCR at the Norwegian 156	  
University of Science and Technology, Trondheim, Norway. 157	  
 158	  
RESULTS 159	  
HBoV1 DNA in NPA, tonsillar tissue, or in both samples, could be detected in 40 patients (21%) 160	  





infection but 12 of 40 patients (30%) reported one or more of the following: mild rhinitis, cough, 162	  
symptoms of otitis, throat pain or upper airway obstruction symptoms on the operation day. In the 163	  
sole adenotomy group 8 of 15 patients (53%) and in the adeno-/tonsillectomy group 4 of 25 patients 164	  
(16%), respectively, reported symptoms (Tables 1-2). 165	  
 166	  
Twenty-eight patients were positive for HBoV1 DNA in NPA only, 7 in tonsillar tissue only and 5 167	  
in both samples. Five sole adenotomy patients had high (>106 copies/ml) viral load in NPA using 168	  
qPCR but were mRNA negative (Table 1). In the tonsillectomy group 9 patients had relatively high 169	  
(>104 copies/ml) viral load in NPA but were mRNA negative and corresponding sera available were 170	  
HBoV1 IgM-negative (Table 2). Only 1 patient gave a (barely) IgM-positive test result, but with a 171	  
stable IgG absorbance in paired samples (Table 2). In all but three patients, the HBoV1 DNA 172	  
finding was accompanied with IgG positivity indicating a prior infection. These three HBoV1 173	  
DNA-positive but seronegative children had, however, prior HBoV2 immunity, which suggest that 174	  
their HBoV1 IgG-negativity can be explained by an immunological phenomenon called original 175	  
antigenic sin [13]. Furthermore, HBoV1-IgG levels did not increase in any of the 7 paired serum 176	  
samples of HBoV1 DNA-positive patients (Table 2). All 29 NPAs and 8 tonsils analyzed were 177	  
HBoV1-mRNA negative (Tables 1-2). Eight NPA samples with HBoV1 DNA loads >104 were 178	  
tested with the beta actin-mRNA PCR, all with strongly positive results. 179	  
 180	  
DISCUSSION 181	  
Our study confirms that HBoV1 can be found in the respiratory tract of patients with chronic and 182	  
recurrent adenotonsillar disease. Quite a high prevalence (21%) of HBoV1 DNA in tonsils and/or 183	  
NPA of elective adeno-/tonsillectomy patients was detected which agrees with earlier studies [8]. 184	  
An even higher prevalence (43%) has been discovered in mainly asymptomatic subjects but the 185	  





and/or myringotomy [14]. We also found relatively high (>104 copies/ml) or high (>106 copies/ml) 187	  
HBoV1 DNA loads in nasopharynx of 13% and 3% our study patients, respectively. However, the 188	  
high DNA loads were not accompanied by positive HBoV1 mRNA or serological responses. Our 189	  
results supported the study hypothesis that HBoV1 was not actively transcribing in persistent 190	  
infection.  191	  
 192	  
The most common laboratory diagnostic method for respiratory infections is qualitative PCR, 193	  
despite the fact that HBoV1 DNA can, due to prolonged presence or intermittent shedding, be 194	  
detected in the nasopharynx for months after a symptomatic respiratory infection [1,6,15]. Previous 195	  
studies have suggested that the DNA amount decreases over time and that high DNA loads (>104 to 196	  
106 copies/ml, depending on the study) would be a sign of acute bocavirus infection [2,5,7,15]. To 197	  
define one specific threshold for high viral load is very demanding due to the various test methods, 198	  
the type and quality of the specimens, and the time of collection. In our study we found high loads 199	  
(>106 copies/ml) of HBoV1 DNA particularly in adenotomy patients of which 3 were asymptomatic 200	  
and 2 had mild respiratory tract symptoms. Only 1 adeno-/tonsillectomy patient with relatively high 201	  
viral load (>104 copies/ml) reported symptoms.  202	  
 203	  
In addition, mRNA of HBoV1 has been used as a marker of viral activity: HBoV1 mRNA can be 204	  
detected in NPA of patients with symptomatic respiratory tract infection but not in asymptomatic 205	  
controls [2,7]. It is known that HBoV1 DNA is stored in adenotonsillar tissue [8]. We wanted to 206	  
investigate the viral activity in tonsils. None of the tonsils showed HBoV1 mRNA regardless of the 207	  
HBoV-DNA load. Furthermore, all NPAs were also mRNA negative, in line with earlier studies of 208	  
non-acute HBoV1 infections[7,8]. Conversely, in previous studies, the detection of HBoV1 mRNA 209	  
in symptomatic patients was associated with high HBoV1 DNA loads [2,7]. In our elective adeno-210	  





associated with concomitant viral replication demonstrated by the lack of mRNA detection. Our 212	  
data suggests that HBoV1 DNA or its high load by qPCR are less specific markers for acute 213	  
HBoV1 infection than mRNA, at least in adenotonsillar surgery subjects. In this respect, our data 214	  
support using HBoV1 mRNA detection as a more reliable method for diagnosing acute infection as 215	  
suggested previously [2,7,8].  216	  
 217	  
Serological results were in line with the clinical findings and did not support acute HBoV1 218	  
infection in any patients. Since most patients studied by serology were ≥5 years of age, they most 219	  
likely have already experienced primary bocavirus infection. The HBoV1 DNA finding in the 220	  
respiratory tract was accompanied by IgG positivity in 18/25 cases (no sera available n=4), of 221	  
which 17 were IgM negative, indicating past infections. The one barely IgM-positive patient with 222	  
HBoV1 DNA in tonsils, showed an already high and stable IgG in paired samples, indicating a 223	  
recent but non-acute infection. In two earlier studies among wheezing children, there has been an 224	  
association of high (>104 or  >106 copies/ml) HBoV1 DNA load with diagnostic serology [2,5]. 225	  
This association could not be found in the current study of primarily asymptomatic tonsillectomy 226	  
patients due to lack of acute infections. We show that persisting HBoV1 DNA can be of relatively 227	  
high loads also in non-acute infections. 228	  
 229	  
This study provides new information about HBoV1 DNA positivity without clinical 230	  
illness/manifestation and also confirms earlier results of HBoV1 diagnosis [2,5–7,15]. Earlier 231	  
studies have focused on young children with respiratory tract infection [5,7,14,15] whereas our 232	  
study had slightly older and mainly asymptomatic adeno- /tonsillectomy patients. A major 233	  
limitation of the current study is that the data set was not complete: 8 of the 45 (18%) HBoV1 PCR-234	  
positive NPA or tonsillar tissue samples were not analyzed by mRNA RT-PCR. Another limitation 235	  





enrollment (n=4), at the follow-up visit (n=10) or both samples (n=4). Serology of the adenotomy 237	  
group was not analyzed. However, this is still the largest study on subjects without acute respiratory 238	  
symptoms that compares different diagnostic methods for HBoV1 infection.  239	  
 240	  
In conclusion, we did not find a correlation between HBoV1 genome load and mRNA detection or 241	  
serology in adeno-/tonsillectomy patients. Our findings support the use of HBoV1 mRNA detection 242	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Table 1. Adenotomy patients with HBoV1 DNA-positive NPA samples 301	  
Case 










HBoV1 DNA load 
(cp/ml) in NPA 
mRNA 
NPA 
B013 4 ROM yes pos 128800 neg 
B038 3 ROM no pos 123800 neg 
B061 2 ROM no pos 550000 neg 
B064 2 ROM no pos 176800 neg 
B066 3 ROM yes pos 141200 neg 
B073 3 ROM no pos 100396800 neg 
B074 5 ROM no pos 36200 neg 
B087 3 ROM yes pos 28269400 neg 
B100 6 AH yes pos 19708800 neg 
B122 8 AH yes pos 358200 neg 
B126 4 AH yes pos 16800 neg 
B129 2 ROM yes pos 117400 neg 
       
B182 2 ROM no pos 20537600 neg 
B184 1 ROM no pos 2227000 neg 
B194 2 ROM yes pos 91600 neg 
       
Abbreviations: y, years; ROM, recurrent otitis media; AH, adenoid hypertrophy; NPA, 302	  
nasopharyngeal aspirate; cp, copies. aOne or more of the following: mild rhinitis, cough, symptoms 303	  

































B004 6 ATH no pos NA neg 0 NA/NA pos neg 
B008 6 ATH no pos 400 neg 0 neg/NA posb neg 
B015 8 ATH no pos 500 neg 0 neg/NA posc neg 
B021 8 ATH no pos 4400 neg 0 neg/NA pos neg 
B028 16 RT, TH no pos NA neg 0 NA/NA negb,d neg 
B051 7 ATH no pos 133200 neg 0 NA/NA posb neg 
B069 8 RT no pos 600 neg 0 neg/NA NA NA 
B113 12 ATH NA pos 119200 neg 0 neg/NA posb neg 
B130 5 ROM, ATH NA pos 30400 neg 0 neg/NA pos neg 
B160 7 ATH yes pos 4000 neg 0 neg/NA pos neg 
B162 6 ATH no pos 210600 neg 0 neg/NA pos neg 
B169 7 RT no pos 7600 neg 0 neg/NA pos neg 
B185 7 ATH NA pos 8600 neg 0 NA/NA posb neg 
B018 22 RT yes neg 0 pos NA NA/NA pos neg 
B019 5 ROM, RT, TH no neg 0 pos NA NA/NA posb pose 
B036 4 ATH NA neg 0 pos NA NA/NA negd neg 
B135 3 ATH no neg 0 pos 2600 NA/neg posc neg 
B193 2 ATH no neg 0 pos 24400 NA/neg NA NA 





B198 3 ROM, ATH, 
recurrent fever 
yes neg 0 pos 10400 NA/neg NA NA 
B056 5 ATH yes pos 307800 pos 58400 neg/neg NA NA 
B082 4 ATH no pos 32200 pos 2000 neg/neg posc neg 
B106 4 ATH no pos 220800 pos 2400 neg/neg posc neg 
B150 5 RT, ATH NA pos 92400 pos 4400 neg/NA posb,d neg 
B197 3 ATH no pos 202600 pos 1400 neg/neg negd neg 
 308	  
Abbreviations: y, years; ATH, adenotonsillar hypertrophy; TH, tonsillar hypertrophy, ROM, 309	  
recurrent otitis media; RT, recurrent tonsillitis; NPA, nasopharyngeal aspirate; cp, copies; NA, not 310	  
available; abs., absorbance (cutoff ≥0.131). 311	  
a One or more of the following: mild rhinitis, cough, symptoms of otitis, throat pain, upper airway 312	  
obstruction symptoms.  313	  
b Paired serum samples; no increase in IgG. 314	  
c No acute-phase serum sample available. 315	  
d  HBoV2 IgG positive; may influence induction of HBoV1 IgG through original antigenic sin [13].  316	  
e Very low absorbance level; 0,147. Together with a stable IgG level in paired samples, the 317	  
interpretation is recent but non-acute HBoV1 infection.  318	  
 319	  
